Article Preview :
The US FDA has granted regulatory approval to a nanoparticulate cancer imaging technology, in the first regulatory approval of an inorganic treatment modality. This will be a welcome affirmation for the many groups working on nanoparticle-based treatment strategies.
The approval was granted to so-called 'âCornell dots'â or C dots, a technology developed by researchers at Cornell University (NY, USA). The C dots consist of dye particles enclosed in an inert silica shell. For human trials, the silica particles will be coated in polyethylene glycol to avoid a foreign body response in the patient. They can also be labeled with organic molecules...